Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner -- Ignore unavailable to you. Want to Upgrade?

To: biopicker who wrote (258)	11/23/1997 8:42:00 PM
From: Steve Lokness	Respond to of 353

Biopicker; Do you have any knowledge of Dr. Welton? Is getting her to join up with ARRS a real accomplishment? What does she bring to the co.? You also mention that the scientific value of ARRS is 172 million. When it is realized that there is some 5oo million potential dollars in announced corporate collaborations and over 300 people working in R&D one can only wonder what the scientific value of Axys will be in 5 years! The share price of ARRS may indeed fall below 9 - who's to say - but even if the co. has problems with drug candidates its hard to imagine going throught hat kind of a cash hoard with a great management and large research staff without coming out with some real winners. Besides, I would think there is always the likelyhood of even more collaborations. Where did the name Axys come from? Steve